Actively Recruiting
Phase 3 Study of Encaleret Tablets Versus Placebo in Adults With Chronic Hypoparathyroidism Including an Open-Label Extension to Assess Long-Term Safety and Efficacy
Led by Calcilytix Therapeutics, Inc., a BridgeBio company · Updated on 2026-11-04
160
Participants Needed
5
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, and tolerability of orally administered encaleret tablets in people with chronic hypoparathyroidism, a condition characterized by low parathyroid hormone levels. This Phase 3, multicenter, randomized, double-blind study compares encaleret to a placebo in participants aged 16 years and older. The study aims to understand how well encaleret controls key biochemical markers related to calcium regulation in this condition. Participants will be randomly assigned to receive either encaleret or a placebo during a 24-week double-blind treatment period. After this phase, participants have the option to continue taking encaleret in an open-label long-term extension for up to 192 weeks. Both encaleret and placebo are given as oral tablets, and the study maintains a parallel-group design. During the study, participants will undergo assessments to monitor albumin-corrected blood calcium and 24-hour urine calcium levels, as well as evaluations of calcium and vitamin D supplement use and symptoms of hypoparathyroidism. Safety and tolerability are closely monitored throughout. The primary outcome is measured at 24 weeks, but participants may continue treatment in the extension phase for long-term observation lasting several years.
CONDITIONS
Brief Title
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
Research Team
M
Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here